fenofibrate has been researched along with Proteinuria in 11 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 5.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| " In the salt-loaded spontaneously hypertensive stroke-prone rat (SHRSP), a model of cardiac hypertrophy and nephropathy that shows mitochondrial alterations in the myocardium, we evaluated the cardiorenal effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist that acts by modulating mitochondrial and peroxisomal fatty acid oxidation." | 3.88 | Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. ( Abbate, M; Castiglioni, L; Crestani, M; Fiaschè, M; Fiordaliso, F; Foray, C; Gelosa, P; Giudici, M; Guerrini, U; Mitro, N; Pignieri, A; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C, 2018) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.39 | Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. ( Balakumar, P; Kadian, S; Mahadevan, N, 2013) |
| "Treatment with fenofibrate (80 mg/kg/day, p." | 1.38 | The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. ( Balakumar, P; Bishnoi, HK; Mahadevan, N, 2012) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.36 | The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. ( Arora, MK; Balakumar, P; Reddy, K, 2010) |
| "Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats." | 1.35 | Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. ( Balakumar, P; Chakkarwar, VA; Singh, M, 2009) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 1.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castiglioni, L | 1 |
| Pignieri, A | 1 |
| Fiaschè, M | 1 |
| Giudici, M | 1 |
| Crestani, M | 1 |
| Mitro, N | 1 |
| Abbate, M | 1 |
| Zoja, C | 1 |
| Rottoli, D | 1 |
| Foray, C | 1 |
| Fiordaliso, F | 1 |
| Guerrini, U | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Gelosa, P | 1 |
| Hu, Z | 1 |
| Huang, S | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Liu, X | 1 |
| Su, D | 1 |
| Tao, Y | 1 |
| Fu, P | 1 |
| Zhang, X | 2 |
| Peng, Z | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Balakumar, P | 4 |
| Chakkarwar, VA | 1 |
| Singh, M | 1 |
| Arora, MK | 1 |
| Reddy, K | 1 |
| Zhou, Y | 1 |
| Kong, X | 1 |
| Zhao, P | 1 |
| Yang, H | 1 |
| Chen, L | 1 |
| Miao, J | 1 |
| Yang, J | 1 |
| Ding, J | 1 |
| Guan, Y | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Nakao, K | 1 |
| Bishnoi, HK | 1 |
| Mahadevan, N | 2 |
| Kadian, S | 1 |
| Wilson, TW | 2 |
| Alonso-Galicia, M | 1 |
| Roman, RJ | 1 |
| Shatara, RK | 1 |
| Quest, DW | 1 |
| Deighan, CJ | 1 |
| Caslake, MJ | 1 |
| McConnell, M | 1 |
| Boulton-Jones, JM | 1 |
| Packard, CJ | 1 |
1 trial available for fenofibrate and Proteinuria
| Article | Year |
|---|---|
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cross-Over Studies; Female; | 2001 |
10 other studies available for fenofibrate and Proteinuria
| Article | Year |
|---|---|
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.
Topics: Acyl-CoA Dehydrogenase; Animals; Cardiomegaly; Cellular Senescence; Fenofibrate; Gene Expression; Hy | 2018 |
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Topics: Adolescent; Adult; Aged; Apolipoprotein E2; Biomarkers; Biopsy; Case-Control Studies; China; Creatin | 2014 |
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Chelating Agents; Diabetes Mellitu | 2009 |
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Ani | 2010 |
Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cytoprotection; Disease Models, Animal; Doxorubicin; Fenof | 2011 |
PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice.
Topics: Animals; Apoptosis; Caspase 3; Cytoprotection; Disease Models, Animal; Doxorubicin; Fenofibrate; Kid | 2011 |
The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Creatine | 2012 |
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetic Nephropathies; Dose-R | 2013 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Fenofibrate lowers blood pressure in two genetic models of hypertension.
Topics: Animals; Blood Glucose; Blood Pressure; Fenofibrate; Hypertension; Hypolipidemic Agents; Male; Prote | 2000 |